Agios Q2 2026: Mitapivat Revenue Surges to $44.7M, FDA Priority Review for Sickle Cell, Cash $965M

summarizeSummary

Agios' Q2 2026 results feature mitapivat revenue surging to $44.7M, FDA Priority Review for sickle cell disease, and a robust cash position of $965M, offset by a $100.7M net loss.

check_boxKey Events · Earnings and Guidance · AGIO

• Mitapivat Revenue Triples

  Worldwide mitapivat net revenues climbed to $44.7 million in Q2 2026, up from $12.5 million in Q2 2025, driven by the U.S. launch of AQVESME in thalassemia and early ex-U.S. demand.

• FDA Priority Review for Sickle Cell

  The FDA accepted the sNDA for mitapivat in sickle cell disease with Priority Review and a PDUFA goal date of November 1, 2026, a potential near-term catalyst.

• Pipeline Advances and Setbacks

  Agios licensed cevidoplenib for ITP with a $25 million upfront payment, advanced AG-236 into Phase 2/3 for polycythemia vera, and discontinued tebapivat in LR-MDS and sickle cell disease.

• Strong Cash Position

  Cash, cash equivalents, and marketable securities totaled $964.8 million as of June 30, 2026, providing runway for commercial execution and pipeline advancement.

auto_awesomeAnalysis · AGIO · Life Sciences

A strong commercial quarter saw mitapivat revenues more than triple year-over-year to $44.7 million, fueled by the U.S. launch of AQVESME in thalassemia. A major catalyst looms with the FDA granting Priority Review for mitapivat in sickle cell disease, setting a PDUFA date of November 1, 2026. The pipeline also advanced through the licensing of cevidoplenib and the progression of AG-236 into Phase 2/3, while tebapivat was discontinued. With $965 million in cash, the company is well-funded to pursue these opportunities, even as the net loss widened to $100.7 million.